How 1st FDA approved once-a-day pill to lower 'bad' cholesterol could…

The FDA has approved Lipfendra (enlicitide), the first oral PCSK9 inhibitor pill for lowering LDL cholesterol, offering a pill-based alternative to injectable cholesterol treatments for patients whose cholesterol remains high despite statins. The drug reduced LDL by 56-59% in trials and targets high-risk patients including those with diabetes, inherited hypercholesterolaemia, and prior heart disease. If you're building adherence tools, compliance software, or patient engagement platforms for chronic disease, you just watched a category (injectable cholesterol drugs) become a tablet category. Merck's shift from injection to pill on a proven molecule is a playbook: find where needle anxiety or inconvenience kills adoption, then solve it with formulation. That gap is your wedge.